New combo aims to stop breast cancer return after failed chemo

NCT ID NCT03756298

Ongoing Disease control Sponsor: National Cancer Center, Korea Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to the chemotherapy pill capecitabine helps prevent cancer from coming back in people with triple-negative breast cancer who still had cancer after initial chemotherapy and surgery. About 284 participants will receive either the combination or capecitabine alone for 8 cycles. The study tracks how many remain cancer-free after 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab and capecitabine
What this could lead to: If successful, this combination could improve long-term survival for people with triple-negative breast cancer who still have cancer after initial chemotherapy.
What could go wrong: This is a mid-stage trial with 284 participants, so results are not yet proven. Adding atezolizumab may increase side effects like immune-related reactions without guaranteeing better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Korea University, Guro hospital

Seoul, 08308, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.